Jefferies Boosts Eli Lilly Price Target to $1,700 as Stock Nears 52-Week High

By TrendSpider Editor

Jefferies (Akash Tewari) reaffirmed its Buy rating on Eli Lilly on November 10, 2026, while raising the price target to $1,700 from a prior target of $1,610. This is the sole analyst action in today's data. The consensus average price target stands at $1,700, aligning directly with Jefferies' update

Jefferies Boosts Eli Lilly Price Target to $1,700 as Stock Nears 52-Week High

Jefferies analyst Akash Tewari reaffirmed a Buy rating on Eli Lilly and Company while raising his price target from $1,610 to $1,700, signaling continued conviction in the pharma giant's growth trajectory. LLY shares are trading at $1,432.91, up 1.47% on the session, and sit comfortably near the top of their 52-week range of $850.51 to $1,453. The updated price target implies meaningful additional upside from current levels, reinforcing the bullish case for one of the most closely watched names in large-cap pharmaceuticals.

Key Drivers of the LLY Stock Move

The forward setup for LLY looks constructive heading into the second half of November, with the stock sitting within roughly 1.4% of its 52-week high and now carrying a freshly raised price target from Jefferies. The $90 increase in Jefferies' target suggests the firm sees improving fundamentals or a strengthened competitive position, likely tied to Lilly's continued dominance in the GLP-1 drug market and its broader pipeline of cardiometabolic and oncology assets. A clean breakout above the $1,453 level would mark a new 52-week high and could attract additional momentum-oriented buying. Traders should monitor volume closely near that resistance zone as a confirming or rejecting signal.

LLY Analyst Ratings and Price Targets

Jefferies (Akash Tewari) reaffirmed its Buy rating on Eli Lilly on November 10, 2026, while raising the price target to $1,700 from a prior target of $1,610. This is the sole analyst action in today's data. The consensus average price target stands at $1,700, aligning directly with Jefferies' updated figure and reflecting strong sell-side confidence in the stock's long-term valuation relative to its current price of $1,432.91.

LLY Seasonality

Historically, large-cap pharmaceutical stocks tend to see increased institutional attention in November as portfolio managers position ahead of year-end, which can amplify the effect of bullish analyst actions during this period. With LLY near multi-year highs in mid-November, seasonal tailwinds may offer an additional supporting layer to the current technical and fundamental setup.

LLY Relative Performance

LLY is trading at $1,432.91, up 1.47% on the session, and is positioned near the upper end of its 52-week range spanning $850.51 to $1,453. The stock has recovered substantially from its 52-week low, more than doubling from that level, underscoring strong relative strength compared to the broader healthcare sector. The stock's proximity to its 52-week high of $1,453 suggests LLY has outperformed many of its large-cap pharma peers over the trailing year, maintaining a leadership position within the sector.

More on LLY

Latest Market News